Cointime

Biohaven Pharmaceutical

company

About

Biohaven is a biopharmaceutical company that develops drug candidates targeting neurological diseases.

  • 1001 - 5000

Highlights

Total Funding Amount
$80M
Funding Rounds
1
Investors
2

Details

Last Funding Type
Series Unknown
Last Funding Money Raised
$80M
Industries
Biotechnology,Health Care,Health Diagnostics,Neuroscience,Pharmaceutical
Founded date
Jan 1, 2013
Number Of Employee
1001 - 5000
Operating Status
Active
Sub-Organizations
BioShin

Biohaven is a clinical-stage biopharmaceutical company. It has a portfolio of late-stage product candidates targeting neurological diseases, including rare disorders. The company product candidates are based on multiple mechanisms-calcitonin gene-related peptide receptor antagonists, glutamate modulators and myeloperoxidase inhibitor. Its pipeline products include BHV3000-301, BHV3000-302, BHV3000-303, and others.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$80M
Biohaven Pharmaceutical has raised a total of $80M in funding over 2 rounds. Their latest funding was raised on Nov 1, 2016 from a Series Unknown round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Nov 1, 2016 Series Unknown $80M 2 — — Detail

Investors

Number of Lead Investors
Number of Investors
—
2
Biohaven Pharmaceutical is funded by 2 investors. Litmore Capital and Knoll Capital Management are the most recent investors.
Investor Name Lead Investor Funding Round
Litmore Capital — Series Unknown
Knoll Capital Management — Series Unknown
Cointime
Содержание
компания